#1
|
|||
|
|||
Âå÷íàÿ àíåìèÿ. Æåëåçî 3.
Äîáðûé äåíü.
28 ëåò ðîñò 168 âåñ 63 Ãåìîòîêðèò è ãåìîãëîáèí âñåãäà íèæå íîðìû , Íàñìîðêîì áîëåþ ïîñòîÿííî. Ýíåðãèè íåò ñèë íåò âîîáùå íè íà ÷òî Õðîíè÷åñêèé òîíçèëëèò Ïîâåðõíîñòíûé ãàñòðèò Ðèôëþêñ Âñþ æèçíü ãåìîãëîáèí ðàâåí äî 110  áåðåìåííîñòü äåðæàëà 100 Ïèëà æåëåçî. Îáèëüíàÿ ìåíñòðóàöèÿ . Ïîñòàðàëàñü ïîñ÷èòàòü .... ëèáî ÿ îøèáëàñü, ëèáî îêîëî 150ìë... Ñêðûòûõ êðîâîòå÷åíèé íåò. Âå÷íî íåðâíàÿ, óñòàëàÿ èç-çà íåäîñòàòêà ýíåðãèè. Çàíÿëàñü ýòèì âîïðîñîì. Ïîäñêàæèòå, ìîæíî ëè ìíå ïîìî÷ü? 25 ôåâðàëÿ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 25 Ìàðòà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#2
|
|||
|
|||
Ïðî÷ëà Âàøè ñòàòüè ïðî àíåìèþ .
Äîáàâëÿþ, ÷òî ä¸ðãàþ íîãàìè ïåðåä çàñûïàíèåì Ìóøêè ëåòàþò èíîãäà Åñëè ðåçêî âñòàþ, îùóùåíèå, ÷òî òåðÿþ ñîçíàíèå Åì òîëüêî ñëàäêîå. Áîëüøå íè÷åãî íå õî÷ó è íå ìîãó Ïðèñóòñòâóåò ïîñòîÿííàÿ òîøíîòà. Ïîÿâèëàñü íåäàâíî Îòäûøêà è òàêèêàðæè÷ ×óâñòâóþ ñåáÿ ïëîõî Ïðèíèìàþ ôåíèáóò óæå íåäåëþ Çàâòîà ñäàþ àíàëèçû íà á9 , á12 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#3
|
|||
|
|||
Âàäèì Âàëåðèåâè÷, ïðîêîììåíòèðóéòå, ïîæàëóéñòà.
Âðà÷è íèêîãäà íè÷åãî íå ãîâîðèëè ïðî ìîé ãåìîãëîáèí. Åñòü è åñòü àíåìèÿ. Íåáîëüøàÿ è áîã ñ íåé. Êàê âû äóìàåòå ëó÷øå òàáëåòêè èëè êàïåëüíèöó æåëåçî? Êàêèå âîîáùå ìîè äåéñòâèÿ äîëæíû áûòü ? Îãðîìíîå ñïàñèáî çà îòâåò |
#4
|
||||
|
||||
â/â âåíîôåð â ñóììå 1000-1200 ìã çà 5-6 ââåäåíèé ïî 200 èëè ìîíîôåð â òîé æå äîçå çà 2 ðàçà
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
|||
|
|||
Öèòàòà:
Ñïàñèáî îãðîìíîå çà îòâåò è ïîìîùü. ß ïîáîÿëàñü äåëàòü êàïåëüíèöó. Ïðèíèìàëà ñîðáèôåð äþðåëåñ 2 ìåñÿöà 2 òàáëåòêè ïîñëå åäû óòðîì è âå÷åðîì. Ãåìîãëîáèí è æåëåçî ïîäíÿëèñü, íî ñìóùàåò ïîêàçàòåëü øèðèíû ýðèòðîöèòîâ. Ïîäñêàæèòå, ýòî ÿâëÿåòñÿ êàêîé-òî ïàòîëîãèåé? Ìîæíî åù¸ êàêèå-íèáóäü àíàëèçû ñäàòü? Íóæíî ëè äàëüøå ïðèíèìàòü æåëåçî. Ôîëèåâàÿ êèñëîòà è â12 â íîðìå Îãðîìíîå ñïàñèáî Àíàëèçû: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#6
|
|||
|
|||
Çàâòðà âûøëþ Ôåððèòèí.
ß åãî òîæå ñäàëà Õîòåëà áû åù¸ íàïèñàòü... ÷òî âñå åãî ó ìåíÿ â ñèíÿêàõ áåç ïðè÷èíû . Áûâàåò íà ðóêàõ íåáîëüøèå , ãî ìàëî, íå òî, ÷òî íà íîãàõ. Ìåíñòðóïöèÿ îáèëüíàÿ . Åñëè ìåñÿö ïðèíèìàòü àñêîðóòèí ïî 3ò â äåíü, òî ìåíñòðóàóèÿ 5 äíåé è íîðìàëüíàÿ. Ãèíåêîëîã ãîâîðèò ñäàòü íà ïîëèìîðôîç ãåíîâ ãåìîñòàçà . Ïîäîçðåâàþò ñâ¸ðòûâàåìîñòü ãåíåòè÷åñêóþ Âíå íîðìû. ×òî äóìàåòå? Ñïàñèáî îãðîìíîå |
#7
|
||||
|
||||
Âñå â íîðìå, à àíèçîöèòîç èëè ïîêàçàòåëü øèðèíû ýðèòðîöèòîâ íîðìàëèçóåòñÿ ÷åðåç 3 ìåñÿöà, êóðñ ëå÷åíèÿ àíåìèè 3-4 ìåñ. ïîëèìîðôèçì ãåíîâ íè÷åãî íå ïîêàæåò, õîòÿ ëàáîðàòîðèþ ôèíàíñîâî ïîääåðæèòå, ïðîñòî ïðèíèìàéòå àñêîðóòèí â êðèòè÷åñêèå äíè äî ìåíîïàóçû - äåøåâëå áóäåò
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
|
#8
|
|||
|
|||
Öèòàòà:
Ó ìåíÿ îñòàëñÿ ïîñëåäíèé âîïðîñ. Îòêóäà ó ìåíÿ ñèíÿêè ... ïî÷åìó áåç ïðè÷èíû? Îñîáåííî íà íîãàõ ... è ýòà ñóïåð äëèòåëüíàÿ è îáèëüíàÿ ìåíñòðóàöèÿ .. |
#9
|
||||
|
||||
Ñ òåì æå óñïåõîì ìîæíî çàäàòü åòîò âîïðîñ è ãàäàëêå îíëàéí èëè íà óëèöå, äëÿ óòî÷íåíèÿ ïðè÷èí ïîâûøåííîé êðîâîòî÷èâîñòè íåîáõîäèìû î÷íûé ñïåöèàëèñò ïî ãåìîñòàçó ïëþñ âûñîêîòåõíîëîãè÷åñêàÿ ëàáîòàòîðèÿ ïî èññëåäîâàíèþ ãåìîñòàçà, òàêèå åñòü â Èçðàèëå è Ãåðìàíèè, åñòü ëè â Ìîñêâå - ìíå íåâåäîìî.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#10
|
||||
|
||||
Äàæå â Èíäèè ýòî äîñòóïíî, íî íå âåçäå:
tests bleeding time (BT), platelet count, prothrombin time (PT), prothrombin consumption index (PCI), activated partial thromboplastin time (APTT), PF3 release with adenosine diphosphate (ADP) at 0 and 20 min, total PF3 assay and platelet Aggregation studies with collagen, ADP, adrenaline, arachidonic acid and ristocetin. Coagulation factor assays, von Willebrand antigen estimation, ristocetin cofactor assay and electron microscopy were performed wherever necessary. Inherited platelet dysfunction was seen in 283 (83.9%) of the patients. Amongst these, isolated PF3 availability defect was seen in 163 (48.4%) cases. Glanzman's thrombasthenia was seen in 30 (8.9%) patients, Storage pool disease in eight (2.4%) patients, arachidonic acid pathway defect in five (1.5%) patients and Bernard-Soulier Syndrome in six (1.8%) patients. In 71 (21.1%) patients, the platelet function defect could not be classified into any specific subtypes. Inherited defects of coagulation were observed in 54 (16%) of the cases. Amongst these, von Willebrand disease (vWD) was the most frequent being seen in 40 (11.9%) of the cases. Factor XIII deficiency was seen in one (0.3%), factor X deficiency in four (1.2%), factor VII deficiency in one (0.3%) and factor XII deficiency in one (0.3%) of the patients. --- Inherited bleeding disorders in Indian women with menorrhagia. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#11
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, äîáðûé äåíü!
Êàê ê ëó÷øåìó ãåìàòîëîãó â ìèðå îáðàùàþñü ê Âàì!) Òîãî, ÷òî áûëî ðàíüøå íåò. ß ÷óâñòâóþ ñåáÿ îòëè÷íî. Èíîãäà, êîíå÷íî, óñòàëîñòü, íî âñå ðàâíî îòëè÷íî! Ñäàëà àíàëèçû. Íóæíî ïðîäîëæàòü æåëåçî? Êñòàòè, ìåíñòðóàöèÿ âñåãäà áûëà 7 äíåé îáèëüíî, òåïåðü 5 äíåé. Íå çíàþ èç-çà æåëåçà èëè íåò. Ñèíÿêè íà íîãàõ ïåðåñòàëè ïîÿâëÿòüñÿ! Ñïàñèáî îãðîìíîå |
#12
|
||||
|
||||
ôåððèòèí ìåíåå 35 óêàçûâàåò íà äåôèöèò æåëåçà, ïðîäîëæàéòå ïðèåì ïð-òà êóðñàìè ïî 3 ìåñ. 1-2 ðàçà â ãîä; åñòü êîñâåííûå íàáëþäåíèÿ, ÷òî êîððåêöèÿ ÆÄ èíîãäà óëó÷øàåò ñèòèàöèþ ñ êðîâîòî÷èâîñòüþ è ñïîñîáñòâóåò óìåíüøåíèþ ìåíñòð. êðîâîïîòåðü
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#13
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, äîáðûé äåíü!
Ïðîøó Âàñ ïðîêîììåíòèðîâàòü àíàëèçû. Ïðî ñåáÿ : æåíùèíà 32 ãîäà ðîñò 168 âåñ 63. Âå÷íî óñòàâøàÿ. Òàêèõàðäèÿ. Ìåíñòðóàöèÿ 🩸 110- 117 ìë ïî Âàøåé òàáëèöå. Ïðèíèìàëà ñîëãàð ìÿãêîå æåëåçî 1 òàáëåòêà 2 ìåñÿöà. (Åù¸ îñòàëàñü áîëüøàÿ áàíêà. Õîðîøî ïåðåíîøó). Ïåðåøëà íà 1 òàáëåòêó â äåíü 2 Ìåñÿöà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Âî âðåìÿ ìåíñòðóàöèè ïðèíèìàëà âñåãäà 2 ãîäà. Êàê ïîíèìàþ, ýôôåêòà íåò. Êàïåëüíèöó äóìàþ ñäåëàòü óæå. Ïîäñêàæèòå, êàê âûáðàòü âðà÷à, ÷òîáû îïàñíî íå áûëî? Ñòðàøíî, ÷òî àëëåðãèÿ íà÷í¸òñÿ èëè ÷òî-òî äðóãîå ... Ìîæíî òàáëåòêàìè èëè íåðåàëüíî? Ïîäíèìàþ ëåò 5..... ýôôåêòà íåò ... Çàðàíåå Ñïàñèáî |
#14
|
||||
|
||||
Ïî÷åìó íåò åôôåêòà? Îí åñòü, ïðîñòî áàëàíñèðóåòñÿ ïîòåðÿìè, åñëè áåðåìåííîñòü ïîêà/áîëüøå íå ïëàíèðóåòñÿ, òî ïîñòàíîâêà Ìèðåíû óáèðàåò ïîòåðè â 2 ðàçà. Åñëè íóæåí âðà÷ â Ìîñêâå äëÿ îðãàíèçàöèè â/â ââåäåíèÿ - ìîãó ïîäñêàçàòü â ëè÷êó, íî ïðèäåòñÿ ââîäèòü 1 ðàç â ïîëãîäà äî ìåíîïàóçû
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#15
|
|||
|
|||
Öèòàòà:
Ïîæàëóéñòà, âûøëèòå êîíòàêòû äëÿ â/â âåäåíèÿ æåëåçà â Ìîñêâå. Âîçìîæíà , àëëåðãèÿ? ß åå áîþñü À åñëè òàáëåòêàìè ïîäíÿòü óâåëè÷èâ äîçó âîçìîæíî? |